Ginsenoside Rb3 (Synonyms: Gypenoside IV)

Cat. No.: HY-N0041 Purity: 99.12%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Ginsenoside Rb3 is extracted from steamed Panax ginseng C. A. Meyer. Ginsenoside Rb3 exhibits inhibitory effect on TNFα-induced NF-κB transcriptional activity with an IC₅₀ of 8.2 μM in 293T cell lines. Ginsenoside Rb3 also inhibits the induction of COX-2 and iNOS mRNA.

For research use only. We do not sell to patients.

Ginsenoside Rb3 Chemical Structure

CAS No. : 68406-26-8

Size	Price	Stock	Quantity
Solid + Solvent
10 mM * 1 mL in DMSO ready for reconstitution	USD 83	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 83	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 40	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 70	In-stock	Estimated Time of Arrival: December 31
50 mg		Get quote
100 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of Ginsenoside Rb3:

Ginsenoside Rb3 (Standard) Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All NF-κB Isoform Specific Products:

View All Isoforms

NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

View All COX Isoform Specific Products:

View All Isoforms

COX COX-1 COX-2 COX-3

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

NF-κB

8.2 μM (IC₅₀, in 293T cell lines)

iNOS

COX-2

In Vitro

Ginsenoside Rb3 (0.1-10 μM) is tested for inhibition of tumor necrosis factor-α (TNF)-induced nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) luciferase reporter activity using a human kidney 293T cell-based assay. Ginsenoside Rb3 shows the significant activity with an IC₅₀ of 8.2 μM. Ginsenoside Rb3 also inhibits the induction of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) messenger Ribonucleic acid (mRNA) in a dose-dependent manner after HepG2 cells have been treated with TNF-α (10 ng/mL)^[1].
Ginsenoside Rb3 (0.1-10 μM) significantly increases cell viability and inhibits lactate dehydrogenase (LDH) release in a dose-dependent manner. PC12 cell viability as determined by MTT reduction is also markedly decreased after the cell is exposed to oxygen and glucose deprivation (OGD)/OGD-Rep. But, when the cells are pretreated with Ginsenoside Rb3 (0.1, 1, and 10 μM), OGD/OGD-Rep induced cell toxicity is significantly attenuated, which is concentration-dependently attenuated by Ginsenoside Rb3 treatment. The viabilities are raised to 52.8%±5.6%, 64.6%±5.7%, and 76.4%±8.8%, respectively, compared with the control group^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Ginsenosides Rb3 is a major compound isolated from Gynostemma pentaphyllum that holistically improves gut microenvironment and induces anti-polyposis in Apc^Min/+ mice. Six-weeks-old mice are subjected to Rb3 treatment, before the appearance of the intestinal polyps. All the mice are monitored for food intake, water consumption, and weight changes. Throughout the experiment, no Rb3/Rd-associated weight loss in mice is observed. In addition, none of the treated mice show variations in food and water consumption. Whereas, the number and size of the polyps are effectively reduced by Rb3 treatments^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

1079.27

Formula

C₅₃H₉₀O₂₂

CAS No.

68406-26-8

Appearance

Solid

Color

White to off-white

SMILES

C[C@]([C@@](C[C@H]1O)([H])[C@]2(CC[C@@H]3O[C@@](O[C@H](CO)[C@@H](O)[C@@H]4O)([H])[C@@H]4O[C@]([C@@H]([C@@H](O)[C@@H]5O)O)([H])O[C@@H]5CO)C)(CC[C@@]2([H])C3(C)C)[C@]6([C@@]1([H])[C@]([C@@](CC/C=C(C)/C)(C)O[C@@H]([C@@H]([C@@H](O)[C@@H]7O)O)O[C@@H]7CO[C@H](OC[C@@H](O)[C@@H]8O)[C@@H]8O)([H])CC6)C

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (92.66 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.9266 mL	4.6328 mL	9.2655 mL
5 mM	0.1853 mL	0.9266 mL	1.8531 mL
10 mM	0.0927 mL	0.4633 mL	0.9266 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (2.32 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (2.32 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.12%

Select Batch:

Data Sheet (298 KB) SDS (393 KB)

COA (260 KB) HNMR (623 KB) RP-HPLC (189 KB) MS (281 KB)

Handling Instructions (2659 KB)

References

[1]. He F, et al. Antitumor effects of dammarane-type saponins from steamed Notoginseng. Pharmacogn Mag. 2014 Jul;10(39):314-7. [Content Brief]

[2]. Zhu JR, et al. Protective effects of ginsenoside Rb(3) on oxygen and glucose deprivation-induced ischemic injury in PC12 cells. Acta Pharmacol Sin. 2010 Mar;31(3):273-80. [Content Brief]

[3]. Huang G, et al. Ginsenosides Rb3 and Rd reduce polyps formation while reinstate the dysbiotic gut microbiota and the intestinal microenvironment in Apc^Min/+ mice. Sci Rep. 2017 Oct 2;7(1):12552. [Content Brief]

Kinase Assay ^[1]	HepG2 cells are seeded at a concentration of 1×10⁵ cells/mL (1.5 mL) in a 12-well plate and grown for 24 h. All cells are then transfected with Pnf-κB-luc plasmid (0.5 μg/well). Transfection are performed by the lipofectamine LTX. After 23 h of transfection, medium is changed to assay medium. After 24 h of transfection, cells are treated with test compounds (e.g., Ginsenoside Rb3; 0.1, 1 and 10 uM) for another 24 hours. After 25 h of transfection, cells are treated with 10 ng/mL of TNF-α for another 23 hours. The luciferase activity of cell lysates is assayed with 100 μL of by luciferase assay kit using an LB 953 Autolumat. Transfections are performed in triplicate, and activation is normalized against α-galactosidase activity^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Assay ^[2]	NGF-differentiated PC12 cells are plated at a density of 1.0×10⁵ cells/mL 2 days before each experiment. To initiate OGD, the cell culture medium is removed and replaced with the glucose-free DMEM, then the cells are incubated at 37°C in an oxygen-free chamber (95% N₂ and 5% CO₂) for 4 h (OGD), and the change in oxygen levels of the culture medium are monitored during incubation in oxygen-free chamber. Following OGD, glucose is added to normal levels (final concentration: 4.5 mg/mL) and cells are incubated under normal growth conditions (95% air and 5% CO₂) for additional 24 h as OGD-reperfusion (OGD-Rep). Ginsenoside Rb3 (0.1, 1, 10 μM) is added to the culture 24 h before OGD treatment and throughout the OGD reperfusion. The control culture is always maintained in normal DMEM and put in the incubator under normal conditions^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[3]	Mice^[3] *Heterozygous male Apc^Min/+ (C57BL/6J-Apc^Min/+) mice* are used. Total 32 male Apc^Min/+ mice (aged 6 weeks) are divided into three groups; 10 mice in the control group and 22 mice equally divided for Rb3 and Rd treatments. The mice are daily gavage with a single dose of Ginsenoside Rb3 or Rd at 20 mg/kg, or solvent control. The treatments are carried out for 8 consecutive weeks. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. He F, et al. Antitumor effects of dammarane-type saponins from steamed Notoginseng. Pharmacogn Mag. 2014 Jul;10(39):314-7. [Content Brief] [2]. Zhu JR, et al. Protective effects of ginsenoside Rb(3) on oxygen and glucose deprivation-induced ischemic injury in PC12 cells. Acta Pharmacol Sin. 2010 Mar;31(3):273-80. [Content Brief] [3]. Huang G, et al. Ginsenosides Rb3 and Rd reduce polyps formation while reinstate the dysbiotic gut microbiota and the intestinal microenvironment in Apc^Min/+ mice. Sci Rep. 2017 Oct 2;7(1):12552. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	0.9266 mL	4.6328 mL	9.2655 mL	23.1638 mL
	5 mM	0.1853 mL	0.9266 mL	1.8531 mL	4.6328 mL
	10 mM	0.0927 mL	0.4633 mL	0.9266 mL	2.3164 mL
	15 mM	0.0618 mL	0.3089 mL	0.6177 mL	1.5443 mL
	20 mM	0.0463 mL	0.2316 mL	0.4633 mL	1.1582 mL
	25 mM	0.0371 mL	0.1853 mL	0.3706 mL	0.9266 mL
	30 mM	0.0309 mL	0.1544 mL	0.3089 mL	0.7721 mL
	40 mM	0.0232 mL	0.1158 mL	0.2316 mL	0.5791 mL
	50 mM	0.0185 mL	0.0927 mL	0.1853 mL	0.4633 mL
	60 mM	0.0154 mL	0.0772 mL	0.1544 mL	0.3861 mL
	80 mM	0.0116 mL	0.0579 mL	0.1158 mL	0.2895 mL

Ginsenoside Rb3 Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Ginsenoside Rb368406-26-8Gypenoside IVGinsenoside Rb 3Ginsenoside Rb-3NF-κBCOXNO SynthaseNuclear factor-κBNuclear factor-kappaBCyclooxygenaseNitric oxide synthasesNOSInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks